| Abstract: | The pathogenesis of atherosclerosis has been studied for over a hundred years, but so far no consensus on this issue doesn't exist. During this time, experts have gone from ideas of atherogenesis as a consequence of excess cholesterol in the diet to complex theories of the pathogenesis of atherosclerosis. Today generally accepted that one of the major risk factor for cardiovascular disease and atherosclerosis is dyslipidemia. When atherogenic dyslipidemia occur expressed disbiotic changes intestine and lead to endotoxemia, bacterial translocation and impaired liver function. The undoubted fact is that the liver plays an important role in the development of atherogenic dyslipidemia, and also is the target organ, which leads to the development of nonalcoholic fatty liver disease (NAFLD). Currently, NAFLD is a major risk factor for cardiovascular disease, it limits the possibility of adequate lipid-lowering therapy, increasing cardiovascular risk. Therefore, in the treatment of atherogenic dyslipidemia with statins and fibrates useful purpose hepatoprotectors. Choosing hepatoprotectors depends on the stage NAFLD. |
